Home

Steven B Ruchefsky

CIK 1569002 · last filed 2017-10-05

Steven B Ruchefsky is a corporate insider who has filed 16 SEC Form 4 insider transactions across 1 company since 2015. Across all open-market trades the lifetime net is −$1.7M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

16

Lifetime Open-Market Net

-$1.69M

Filer Profile

Reported Address
200 ROUTE 31 NORTH
SUITE 104
FLEMINGTON, NJ 08822
Related Filers
S DONALD SUSSMAN — 1 joint filings, latest 2016-09-08
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Kite Pharma, Inc. (KITE) Delisted Director 1,154,256 — — -$1.69M 5 2017-06-22

Recent Filings

16 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2017-10-05 — Mixed −207,836 $0
2017-06-22 Kite Pharma, Inc. (KITE) Delisted Grant (A) +2,410 $0 EDGAR
2017-06-16 Kite Pharma, Inc. (KITE) Delisted Sell (S) −20,000 -$1.79M EDGAR
2017-05-10 Kite Pharma, Inc. (KITE) Delisted Buy (P) +1,400 $97.3K EDGAR
2016-06-03 Kite Pharma, Inc. (KITE) Delisted Grant (A) +1,950 $0 EDGAR
2016-04-11 — Grant (A) — $0
2016-01-14 — Buy (P) +2,876,633 $1.01M
2015-11-06 — Grant (A) — $0
2015-06-17 Kite Pharma, Inc. (KITE) Delisted Grant (A) — $0 EDGAR
2014-11-06 — Mixed — $0
Showing 1–10 of 16
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.